This retrospective study will evaluate the association of biomarkers and the treatment response of patients with chronic hepatitis B, who have completed therapy with Pegasys (peginterferon alfa-2a) ± lamivudine. For the analysis stored serum samples obtained from patients will be used; no actual patients are involved.
Study Type
OBSERVATIONAL
Enrollment
269
Unnamed facility
Herston, Queensland, Australia
Unnamed facility
Fitzroy, Victoria, Australia
Interleukin-28B (IL-28B) genotype in stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine
Time frame: Samples up to 72 weeks of treatment
Single nucleotide polymorphisms (SNP) of rs12356193 in stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine
Time frame: Samples up to 72 weeks of treatment
IL-28B concentration at baseline and during treatment with Pegasys +/- lamivudine from stored serum samples of patients with chronic hepatitis B
Time frame: Samples up to 72 weeks of treatment
Protein/RNA biomarker evaluation from stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine
Time frame: Samples up to 72 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Clichy, France
Unnamed facility
Hong Kong, Hong Kong
Unnamed facility
Hong Kong, Hong Kong
Unnamed facility
Bari, Apulia, Italy
Unnamed facility
Brescia, Lombardy, Italy
Unnamed facility
Cagliari, Sardinia, Italy
Unnamed facility
Pisa, Tuscany, Italy
Unnamed facility
Auckland, New Zealand
...and 17 more locations